Annexin Q3 2023 - Our Comment
2023-10-19 08:00:00
Redeye returns with an update following Annexin’s Q3 report. We note that it has been an eventful quarter for the company, including progress with its RVO and Cancer tracks. The report came in as expected but we expect the company to present a financing solution relatively soon.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/